Read on Twitter
My take is: I don’t think Moderna or Pfizer actually believe their vaccine will have durable efficacy after one dose.
One problem with pushing for a large single-dose study is this. And you’ll need the same sites, investigators, volunteers, money for ph3 studies of Novavax, Sanofi, and others on the horizon. Some people don’t realize how strapped the vaccine study infrastructure is right now. https://twitter.com/k_stephensonmd/status/1343376207757373440
It’s very easy to say we should throw in another large study but there’s definitely an opportunity cost, and if the probability of success is low it may make sense to just forge ahead with the other vaccine studies out there
Perfect analogy. “We need to study hydroxychloroquine further!” was something people said a lot this year. But those studies also take away from other studies that may be more promising. Bandwidth is not infinite and we’re already stretching the limits of what can be done. https://twitter.com/jallepap/status/1343513868086243328
I guess you can add to this that the US government does not appear particularly interested in a single-dose mRNA regimen right now https://twitter.com/EricTopol/status/1343675160583315456
I think the advocates for a single-dose regimen study will have to wait and see what observational real-world data look like. Neither Moderna nor Pfizer are planning studies and I don’t see who will fund an investigator-initiated study. https://www.axios.com/pfizer-single-dose-data-716702dd-324f-42b9-b88d-07df43ca198a.html
Let me be clear to anyone now reading the thread: I am not in any way commenting on the UK’s decision to delay the second dose of mRNA vaccines. The question I’m talking about is whether a single-dose regimen is going to be studied. Delaying dose 2 is an entirely different matter
